Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARDX

ARDX - Ardelyx Inc Stock Price, Fair Value and News

9.47USD-0.20 (-2.07%)Market Closed
Watchlist

Market Summary

USD9.47-0.20
Market Closed
-2.07%

ARDX Alerts

  • 2 major insider sales recently.
  • JANUS HENDERSON GROUP PLC reported owning 10.6% of ARDX [2024-02-13]
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

ARDX Stock Price

View Fullscreen

ARDX RSI Chart

ARDX Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-30.54

Price/Sales (Trailing)

16.21

EV/EBITDA

-33.68

Price/Free Cashflow

-22.4

ARDX Price/Sales (Trailing)

ARDX Profitability

Operating Margin

95.53%

EBT Margin

-52.65%

Return on Equity

-39.6%

Return on Assets

-22.2%

Free Cashflow Yield

-4.46%

ARDX Fundamentals

ARDX Revenue

Revenue (TTM)

124.5M

Rev. Growth (Yr)

-22.22%

Rev. Growth (Qtr)

-39.06%

ARDX Earnings

Earnings (TTM)

-66.1M

Earnings Growth (Yr)

-369.3%

Earnings Growth (Qtr)

-534.48%

Breaking Down ARDX Revenue

Last 7 days

-7.2%

Last 30 days

0.1%

Last 90 days

108.8%

Trailing 12 Months

181.6%

How does ARDX drawdown profile look like?

ARDX Financial Health

Current Ratio

4.88

ARDX Investor Care

Shares Dilution (1Y)

17.06%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202363.1M82.9M134.3M124.5M
20224.0M5.2M9.0M52.2M
202112.9M12.4M10.9M10.1M
20206.8M8.3M8.0M7.6M
20193.3M3.9M4.6M5.3M
201842.8M43.7M44.5M2.6M
201700042.0M
20160000
201529.0M38.0M30.4M24.0M
201430.9M32.8M33.8M31.6M
201311.3M17.2M23.0M28.9M
20120005.4M

Tracking the Latest Insider Buys and Sells of Ardelyx Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 20, 2024
felsch robert ora
sold
-20,571
8.7463
-2,352
see remarks
Feb 20, 2024
renz justin a
sold
-46,714
8.7463
-5,341
chief financial officer
Feb 20, 2024
raab michael
sold
-200,439
8.7463
-22,917
president & ceo
Feb 20, 2024
grammer elizabeth a
sold
-38,763
8.7463
-4,432
see remarks
Feb 20, 2024
williams laura a
sold
-42,008
8.7463
-4,803
chief medical officer
Feb 20, 2024
blanks robert
sold
-43,880
8.7463
-5,017
see remarks
Feb 20, 2024
rosenbaum david p.
sold
-43,880
8.7463
-5,017
chief development officer
Feb 20, 2024
rodriguez susan
sold
-60,594
8.7463
-6,928
chief commercial officer
Feb 20, 2024
rosenbaum david p.
sold
-20,064
8.7463
-2,294
chief development officer
Feb 08, 2024
rosenbaum david p.
sold
-140,846
9.1792
-15,344
chief development officer

1–10 of 50

Which funds bought or sold ARDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Quarry LP
sold off
-100
-65,280
-
-%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
added
152
31,198,500
42,194,100
0.69%
Feb 20, 2024
Able Wealth Management LLC
new
-
2,015
2,015
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
34.47
7,374,000
14,442,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
1,060
3,100
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-2,243,000
-
-%
Feb 15, 2024
Legal & General Group Plc
added
11.33
558,382
1,365,470
-%
Feb 15, 2024
BARCLAYS PLC
added
15.32
5,820,000
13,552,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
60.17
4,003,010
6,794,620
-%
Feb 15, 2024
GTS SECURITIES LLC
added
280
1,166,980
1,410,660
-%

1–10 of 40

Are Funds Buying or Selling ARDX?

Are funds buying ARDX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARDX
No. of Funds

Unveiling Ardelyx Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
janus henderson group plc
10.6%
24,658,820
SC 13G/A
Feb 13, 2024
vanguard group inc
5.61%
13,026,046
SC 13G
Jan 31, 2024
millennium management llc
0.0%
6,286
SC 13G/A
Jan 30, 2024
state street corp
7.37%
17,102,598
SC 13G/A
Jan 26, 2024
blackrock inc.
7.2%
16,776,055
SC 13G
Jul 10, 2023
state street corp
10.46%
22,437,564
SC 13G
Feb 14, 2023
deep track capital, lp
0%
0
SC 13G/A
Feb 07, 2023
millennium management llc
5.1%
10,162,045
SC 13G
Jan 27, 2023
millennium management llc
5.4%
10,634,329
SC 13G/A
Jan 10, 2023
janus henderson group plc
10.5%
19,774,333
SC 13G

Recent SEC filings of Ardelyx Inc

View All Filings
Date Filed Form Type Document
Feb 28, 2024
4
Insider Trading
Feb 28, 2024
S-8
Employee Benefits Plan
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading
Feb 22, 2024
4
Insider Trading

What is the Fair Value of ARDX?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Ardelyx Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
4.1B
726.4M
-12.60% 32.37%
-66.62
5.62
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
SMALL-CAP
1.5B
398.2M
-3.38% -9.50%
21.06
3.78
85.90% -14.05%
738.0M
983.7M
-9.17% -57.89%
-1.35
0.75
-50.36% 17.16%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Ardelyx Inc News

Latest updates
MarketBeat14 hours ago
AmericanBankingNEWS27 Feb 202406:25 am
TradingView23 Feb 202408:37 pm
Seeking Alpha23 Feb 202401:23 am
The Washington Post23 Feb 202412:26 am

Ardelyx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-39.1%34,363,00056,391,00022,333,00011,369,00044,178,0004,986,0002,526,000468,0001,029,0001,173,0001,313,0006,582,0001,809,0002,713,0001,836,0001,213,0002,250,0003,013,0002,037,0001,061,00085,000
Cost Of Revenue----1,537,0003,162,000732,000138,00085,000---1,000,0004,000-141,000--600,000---
Gross Profit-----------------2,250,0002,413,00018,000-85,000
Costs and Expenses36.8%56,503,50041,301,00035,468,00037,433,00032,947,50026,134,00028,603,00028,275,00036,302,00043,409,00046,145,00038,587,00029,452,00019,874,00026,043,00022,982,00021,098,00025,102,00024,846,00025,498,000-
Operating Expenses----------------22,982,00021,098,00024,502,00024,846,00025,498,00027,461,000
  S&GA Expenses46.2%47,748,00032,664,00027,186,00026,803,00019,731,00018,667,00018,862,00019,339,00015,334,00019,714,00020,124,00017,131,00011,343,0007,634,0007,038,0007,138,0006,857,0006,922,0005,371,0005,117,0005,425,000
  R&D Expenses10.3%9,524,0008,637,0008,282,0009,093,0009,142,0007,467,0009,741,0008,851,00020,968,00023,695,00026,021,00020,456,00018,105,00012,240,00018,864,00015,844,00014,241,00017,580,00019,475,00020,381,00022,036,000
EBITDA Margin-203.1%-0.48-0.16-0.62-0.98-1.20-12.12-24.70-36.68-14.94-13.10-9.51-7.56---------
Interest Expenses57.2%1,740,0001,107,0001,075,0001,028,000991,000886,000777,000746,000984,0001,216,0001,202,0001,100,0001,314,0001,202,0001,226,0001,357,0001,398,0001,443,0001,451,0001,434,000-
Income Taxes66.5%333,000200,000-14,000--6,0002,000-1,0002,0001,0002,000----301,000-2,000-2,000
Earnings Before Taxes-516.9%-28,469,0006,829,000-17,121,000-26,759,00010,695,000-22,893,000-26,932,000-28,069,000-36,234,000-43,586,000-45,187,000-33,154,000-28,874,000-18,108,000-24,956,000-22,373,000-19,790,000-23,238,000-25,467,000-26,142,000-27,864,000
EBT Margin-168.2%-0.53-0.20-0.68-1.04-1.29-12.67-25.95-38.43-15.66-13.86-10.09-8.12---------
Net Income-534.5%-28,802,0006,629,000-17,121,000-26,773,00010,695,000-22,893,000-26,938,000-28,071,000-36,234,000-43,587,000-45,189,000-33,155,000-28,876,000-18,108,000-24,956,000-22,373,000-19,790,000-23,539,000-25,467,000-26,144,000-27,862,000
Net Income Margin-168.3%-0.53-0.20-0.68-1.05-1.29-12.67-25.95-38.43-15.66-13.86-10.09-8.12---------
Free Cashflow59.6%-8,761,000-21,661,000-14,830,000-44,809,00014,229,000-25,427,000-31,281,000-27,620,000-39,374,000-35,034,000-35,015,000-44,995,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets2.8%298289211217190145132129150171205210202199217235260119138166183
  Current Assets2.0%246241162167154120114114134153186205195194212229252111127154176
    Cash Equivalents-36.4%21.0034.0030.0092.0096.0062.0053.0047.0072.0075.0087.0084.0091.0091.0010010618193.0090.0092.0079.00
  Inventory-------5.003.00-------------
  Net PPE-9.6%1.001.001.001.001.001.002.002.002.003.003.002.002.002.003.003.003.004.004.005.006.00
Liabilities33.1%13198.0088.0092.0092.0078.0079.0065.0067.0089.0087.0079.0075.0067.0071.0068.0073.0070.0069.0074.0068.00
  Current Liabilities15.8%50.0044.0062.0063.0066.0052.0049.0048.0053.0069.0058.0042.0028.0017.0034.0023.0022.0018.0016.0021.0018.00
    LT Debt, Current------27.0026.0026.0032.00------------
Shareholder's Equity-12.7%16719112312598.0067.0053.0064.0083.0081.0011813112613114616818749.0069.0092.00116
  Retained Earnings-3.5%-846-817-824-806-780-790-767-741-712-676-633-587-554-525-507-482-460-440-417-391-365
  Additional Paid-In Capital0.4%1,0131,009947932879858821805796758751719681657654651647490486483481
Shares Outstanding0.1%23223221821419916513813113010010097.00---------
Float-------89.00---769---612---126--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations59.4%-8,718-21,467-14,737-44,79514,284-25,427-31,281-27,620-39,469-34,589-34,276-44,217-17,590-19,877-19,022-24,946-11,137-20,614-27,820-16,913-18,436
  Share Based Compensation12.6%3,9303,4893,1992,9121,9261,8483,2543,7223,4712,2623,2193,0872,4342,5272,6742,9482,2123,8791,9231,9222,250
Cashflow From Investing9.6%-29,567-32,697-59,207-9,7771,441-83215,4742,33222,09618,1338,2342,485-3,5709,59413,417-50,883-55,46123,44825,40529,98122,190
Cashflow From Financing-55.1%25,98857,87311,51550,91918,78734,47922,138-63.0014,5134,99928,71734,77021,183798204591155,0582135.00200-1.00

ARDX Income Statement

2023-12-31
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 124,456$ 52,158$ 10,097
Cost of goods sold:   
Total cost of goods sold17,7954,1171,000
Operating expenses:   
Research and development35,53635,20191,140
Selling, general and administrative134,40176,59972,303
Total operating expenses169,937111,800163,443
Loss from operations(63,276)(63,759)(154,346)
Interest expense(4,950)(3,400)(4,502)
Non-cash interest expense related to the sale of future royalties(3,924)(1,673)0
Other income, net6,6301,633687
Loss before provision for income taxes(65,520)(67,199)(158,161)
Provision for income taxes54784
Net loss$ (66,067)$ (67,207)$ (158,165)
Net loss per share of common stock - basic (in dollars per share)$ (0.30)$ (0.42)$ (1.52)
Net loss per share of common stock - diluted (in dollars per share)$ (0.30)$ (0.42)$ (1.52)
Shares used in computing net loss per share - basic (in shares)219,331,253158,690,083104,205,645
Shares used in computing net loss per share - diluted (in shares)219,331,253158,690,083104,205,645
Comprehensive loss:   
Net loss$ (66,067)$ (67,207)$ (158,165)
Unrealized gains (losses) on available-for-sale securities278(48)(2)
Comprehensive loss(65,789)(67,255)(158,167)
Product sales, net   
Revenues:   
Total revenues82,52615,6000
Cost of goods sold:   
Total cost of goods sold2,3235660
Licensing revenue   
Revenues:   
Total revenues35,80935,0315,013
Product supply revenue   
Revenues:   
Total revenues6,1211,527907
Collaborative development revenue   
Revenues:   
Total revenues004,177
Other cost of revenue   
Cost of goods sold:   
Total cost of goods sold$ 15,472$ 3,551$ 1,000

ARDX Balance Sheet

2023-12-31
BALANCE SHEETS - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 21,470,000$ 96,140,000
Short-term investments162,829,00027,769,000
Accounts receivable22,031,0007,733,000
Inventory12,448,0003,282,000
Prepaid commercial manufacturing18,925,00013,567,000
Prepaid expenses and other current assets8,408,0005,112,000
Total current assets246,111,000153,603,000
Property and equipment, net1,009,0001,223,000
Inventory, non-current37,039,00025,064,000
Prepaid commercial manufacturing, non-current4,235,0000
Right-of-use assets5,589,0009,295,000
Other assets3,596,000881,000
Total assets297,579,000190,066,000
Current liabilities:  
Accounts payable11,138,00010,859,000
Accrued compensation and benefits12,597,0007,548,000
Current portion of operating lease liability4,435,0003,894,000
Current portion of long-term debt026,711,000
Deferred revenue7,182,0004,211,000
Accrued expenses and other current liabilities15,041,00012,380,000
Total current liabilities50,393,00065,603,000
Operating lease liability, net of current portion1,725,0005,855,000
Long-term debt, net of current portion49,822,0000
Deferred revenue, non-current8,644,0009,025,000
Deferred royalty obligation related to the sale of future royalties20,179,00011,254,000
Total liabilities130,763,00091,737,000
Commitments and contingencies (Note 20)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding00
Common stock, $0.0001 par value; 500,000,000 and 300,000,000 shares authorized; 232,453,190 and 198,575,016 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.23,00020,000
Additional paid-in capital1,012,773,000878,500,000
Accumulated deficit(846,204,000)(780,137,000)
Accumulated other comprehensive income (loss)224,000(54,000)
Total stockholders’ equity166,816,00098,329,000
Total liabilities and stockholders’ equity$ 297,579,000$ 190,066,000
ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEwww.ardelyx.com
 EMPLOYEES133

Ardelyx Inc Frequently Asked Questions


What is the ticker symbol for Ardelyx Inc? What does ARDX stand for in stocks?

ARDX is the stock ticker symbol of Ardelyx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ardelyx Inc (ARDX)?

As of Wed Feb 28 2024, market cap of Ardelyx Inc is 2.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARDX stock?

You can check ARDX's fair value in chart for subscribers.

What is the fair value of ARDX stock?

You can check ARDX's fair value in chart for subscribers. The fair value of Ardelyx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ardelyx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ardelyx Inc a good stock to buy?

The fair value guage provides a quick view whether ARDX is over valued or under valued. Whether Ardelyx Inc is cheap or expensive depends on the assumptions which impact Ardelyx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDX.

What is Ardelyx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 28 2024, ARDX's PE ratio (Price to Earnings) is -30.54 and Price to Sales (PS) ratio is 16.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDX PE ratio will change depending on the future growth rate expectations of investors.